Opdivo + Yervoy significantly improved overall survival compared to lenvatinib or sorafenib as first-line treatment for patients with advanced hepatocellular carcinoma in CheckMate -9DW trial – BMS
Bristol Myers Squibb announced the first presentation of results from the Phase III CheckMate -9DW trial evaluating the dual immunotherapy combination of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared… read more.